---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-103053"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:38:43.878322+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dianthus Therapeutics raises ~$673.5M in public offering of common stock and pre-funded warrants

## Summary
- Offering of 7,313,582 shares at $81.00/share and pre-funded warrants for 402,468 shares at $80.999/share.
- Underwriters exercised in full option to purchase additional 1,157,407 shares on March 11, 2026.
- Net proceeds expected to be approximately $673.5 million after underwriting discounts and expenses.
- Offering expected to close March 12, 2026; securities offered under shelf registration statement.

## SEC filing metadata
- accession: 0001193125-26-103053
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312526103053/0001193125-26-103053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312526103053/d43448d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-103053
- JSON: https://secwatch.observer/filing/0001193125-26-103053.json
- Plain text: https://secwatch.observer/filing/0001193125-26-103053.txt

## Key facts
- Material Agreements
  Dianthus Therapeutics, Inc. /DE/ entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters valued at approximately $673.5 million (effective 2026-03-10).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters
  - Value: approximately $673.5 million
  - Effective: 2026-03-10
  source text: On March 10, 2026, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 7,313,582 shares of the Company’s common stock at a public offering price of $81.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 402,468 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a public offering price of $80.999 per share, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each Pre-Funded Warrant (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312526103053/0001193125-26-103053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.